

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF CALIFORNIA

IN RE: INCRETIN-BASED THERAPIES  
PRODUCTS LIABILITY LITIGATION

As to all related and member cases

Case No.:  
13md2452 AJB (MDD)

**ORDER DIRECTING CLERK OF  
COURT TO ENTER JUDGMENT**

On November 9, 2015, the Court issued an order granting Defendants Merck Sharp and Dohme Corp., Amylin Pharmaceuticals, LLC, Eli Lilly and Company, and Novo Noridsk Inc.’s (collectively referred to as “Defendants”) motion for summary judgment on the affirmative defense of preemption and denied Plaintiffs’ cross motion for summary judgment. (Doc. No. 1539.) In accordance with that order, the Court hereby instructs the Clerk of Court to enter judgment in the above and related and member cases alleging claims of pancreatic cancer against Defendants in favor of Defendants and against Plaintiffs. Judgment by the Clerk of Court docketed in 13md2452 will apply to all individual and member cases asserting claims of pancreatic cancer against Defendants.

///

1 This order does not apply to related cases consolidated or associated to *Childress v.*  
2 *Amylin Pharmaceuticals, LLC*, Case No. 13cv1114, *Suefert v. Merck Sharp and Dohme*  
3 *Corp.*, Case No. 13cv2169, or *Elosegui v. Bristol-Myers Squibb Company*, Case No.  
4 15cv198.

5 For the purposes of appeal, Case No. 13md2452 will remain administratively open  
6 to permit the filing of new claims.

7  
8 **IT IS SO ORDERED.**

9 Dated: November 30, 2015

10   
11 Hon. Anthony J. Battaglia  
12 United States District Judge  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28